


Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Aug-2024  
 Document Type: USP Monographs  
 DocId: GUID-FA3EE285-C60A-440B-B5B4-15518E76B450\_6\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M56600\\_06\\_01](https://doi.org/10.31003/USPNF_M56600_06_01)  
 DOI Ref: bnr78

© 2025 USPC  
 Do not distribute

## Nicardipine Hydrochloride



$C_{26}H_{29}N_3O_6 \cdot HCl$  515.99

3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester, monohydrochloride; 2-(Benzylmethylamino)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate monohydrochloride CAS RN®: 54527-84-3; UNII: K5BC5011K3.

Nicardipine free base

$C_{26}H_{29}N_3O_6$  479.53 CAS RN®: 55985-32-5; UNII: CZ5312222S.

### DEFINITION

Nicardipine Hydrochloride contains NLT 98.0% and NMT 102.0% of nicardipine hydrochloride ( $C_{26}H_{29}N_3O_6 \cdot HCl$ ), calculated on the dried basis.

### IDENTIFICATION

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197K or 197A
- B. The retention time of the major peak of the *Sample* solution corresponds to that of the *Standard* solution, as obtained in the Assay.
- C. [IDENTIFICATION TESTS—GENERAL \(191\), Chemical Identification Tests, Chloride](#)

**Sample solution:** 2.5 mg/mL in [methanol](#)

**Acceptance criteria:** Meets the requirements

### ASSAY

#### • PROCEDURE

Protect all solutions from light.

**Buffer:** 6.8 g/L of [monobasic potassium phosphate](#) in [water](#). Adjust the solution with potassium hydroxide to a pH of 4.8.

**Solution A:** [Acetonitrile](#) and [methanol](#) (90:10)

**Mobile phase:** *Solution A* and *Buffer* (38:62)

**System suitability solution:** 0.02 mg/mL each of [USP Nicardipine Hydrochloride RS](#), [USP Nicardipine Related Compound B RS](#), [USP Nicardipine Related Compound C RS](#), and [USP Nicardipine Related Compound D RS](#) in *Mobile phase*

**Standard solution:** 0.1 mg/mL of [USP Nicardipine Hydrochloride RS](#) in *Mobile phase*

**Sample solution:** 0.1 mg/mL of Nicardipine Hydrochloride in *Mobile phase*. [NOTE—Sonication may be necessary for complete dissolution.]

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 237 nm

**Column:** 4.6-mm × 25-cm; 4-μm packing [L7](#)

**Column temperature:** 35°

**Flow rate:** 1.2 mL/min

**Injection volume:** 20 μL

**Run time:** NLT 2 times the retention time of the nicardipine peak

#### System suitability

**Samples:** System suitability solution and Standard solution

[NOTE—The relative retention times for nicardipine, nicardipine related compound D, nicardipine related compound C, and nicardipine related compound B are 1.00, 1.10, 1.43, and 1.93 respectively.]

### Suitability requirements

**Resolution:** NLT 1.5 between nicardipine and nicardipine related compound D, *System suitability solution*

**Tailing factor:** NMT 2.0, *Standard solution*

**Relative standard deviation:** NMT 0.73%, *Standard solution*

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of nicardipine hydrochloride ( $C_{26}H_{29}N_3O_6 \cdot HCl$ ) in the portion of Nicardipine Hydrochloride taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak response of nicardipine from the *Sample solution*

$r_s$  = peak response of nicardipine from the *Standard solution*

$C_s$  = concentration of [USP Nicardipine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_u$  = concentration of Nicardipine Hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the dried basis

### IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

• **ORGANIC IMPURITIES**

Protect all solutions from light.

**Buffer, Solution A, Mobile phase, and System suitability solution:** Prepare as directed in the Assay.

**Standard solution 1:** 3 µg/mL of [USP Nicardipine Hydrochloride RS](#) in *Mobile phase*

**Standard solution 2:** 0.6 µg/mL of [USP Nicardipine Related Compound B RS](#) in *Mobile phase*

**Sensitivity solution:** 0.3 µg/mL of [USP Nicardipine Hydrochloride RS](#) from *Standard solution 1* in *Mobile phase*

**Sample solution:** 0.6 mg/mL of Nicardipine Hydrochloride in *Mobile phase*. [NOTE—Sonication may be necessary for complete dissolution.]

**Chromatographic system:** Proceed as directed in the Assay, except for the *Run time*.

**Run time:** NLT 4 times the retention time of nicardipine

### System suitability

**Samples:** *System suitability solution, Standard solution 1, Standard solution 2, and Sensitivity solution*

[NOTE—See [Table 1](#) for the relative retention times.]

### Suitability requirements

**Resolution:** NLT 1.5 between nicardipine and nicardipine related compound D; NLT 1.5 between nicardipine related compound D and nicardipine related compound C, *System suitability solution*

**Relative standard deviation:** NMT 2%, *Standard solution 1* and *Standard solution 2*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

### Analysis

**Samples:** *Standard solution 1, Standard solution 2, and Sample solution*

Calculate the percentage of nicardipine related compound B in the portion of Nicardipine Hydrochloride taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak response of nicardipine related compound B from the *Sample solution*

$r_s$  = peak response of nicardipine related compound B from *Standard solution 2*

$C_s$  = concentration of [USP Nicardipine Related Compound B RS](#) in *Standard solution 2* (µg/mL)

$C_u$  = concentration of Nicardipine Hydrochloride in the *Sample solution* (µg/mL)

Calculate the percentage of nicardipine related compound C and nicardipine related compound D or any unspecified impurity in the portion of Nicardipine Hydrochloride taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_U$  = peak response of each specified and unspecified impurity from the *Sample solution*

$r_S$  = peak response of nicardipine from *Standard solution 1*

$C_S$  = concentration of [USP Nicardipine Hydrochloride RS](#) in *Standard solution 1* ( $\mu\text{g/mL}$ )

$C_U$  = concentration of Nicardipine Hydrochloride in the *Sample solution* ( $\mu\text{g/mL}$ )

**Acceptance criteria:** See [Table 1](#). The reporting threshold is 0.05%.

**Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Nicardipine	1.0	—
Nicardipine related compound D (nicardipine bis analog)	1.1	0.5
Nicardipine related compound C (nicardipine dimethyl ester)	1.4	0.5
Nicardipine related compound B (nicardipine pyridine analog)	2.0	0.1
Any unspecified impurity	—	0.10
Total impurities	—	1.0

#### SPECIFIC TESTS

- [Loss on Drying \(731\)](#)

**Analysis:** Dry at 105°, protected from light, to constant weight.

**Acceptance criteria:** NMT 0.5%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tightly closed containers, protected from light. Store at room temperature.

**Change to read:**

- [USP Reference Standards \(11\)](#)

[USP Nicardipine Hydrochloride RS](#)

[USP Nicardipine Related Compound B RS](#)

▲3-(2-[Benzyl(methyl)amino]ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate oxalate.▲ (ERR 1-Aug-2024)

$\text{C}_{26}\text{H}_{27}\text{N}_3\text{O}_6 \cdot \text{C}_2\text{H}_2\text{O}_4$  567.55

[USP Nicardipine Related Compound C RS](#)

Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.

$\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}_6$  346.34

[USP Nicardipine Related Compound D RS](#)

▲Bis(2-[benzyl(methyl)amino]ethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride.▲ (ERR 1-Aug-2024)

$\text{C}_{35}\text{H}_{40}\text{N}_4\text{O}_6 \cdot 2\text{HCl}$  685.64

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NICARDIPINE HYDROCHLORIDE	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 46(6)

**Current DocID: GUID-FA3EE285-C60A-440B-B5B4-15518E76B450\_6\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M56600\\_06\\_01](https://doi.org/10.31003/USPNF_M56600_06_01)**

**DOI ref: [bnr78](#)**

OFFICIAL